Unity Walk > The Parkinson Alliance Research Grants 2018

The Parkinson Alliance is using its 2018 distribution to fund:

Registry for the Advancement of DBS in Parkinson’s Disease (RAD-PD)

PROJECT TITLE:  Registry for the Advancement of DBS in Parkinson’s Disease (RAD-PD)

Investigator/Author: Joohi Jimenez-Shahed, MD and Jim McInerney, MD

Objective: This project will identify the best practices surrounding DBS therapy, identify the adverse effects (and determinants) of DBS therapy, and identify the health economics and disparities related to DBS therapy, thereby helping clinicians identify ways to improve DBS treatment processes and patient outcomes.

Background: Many clinical questions about DBS therapy cannot be practically answered through traditional clinical trials methodology.  RAD-PD will be conducted as a quality improvement project, a form of health effectiveness research that is focused on measuring and monitoring outcomes in order to secure positive change.

Methods/Design: This study has 2 phases.  In the first phase, we will use an neuroimaging method called positron emission tomography and gradually escalating doses of varenicline to find the most appropriate dose for Parkinson disease patients.  In the second phase, we will administer the selected dose of varenicline to Parkinson disease patients in a double-blind crossover trial. Laboratory measures of gait and balance will be obtained on and off varenicline.  This will allow us to determine if varenicline, or similar drugs, should be pursued as treatments for Parkinson disease.  

Relevance to Diagnosis/Treatment of Parkinson’s Disease: Relevance to Diagnosis/Treatment of Parkinson’s disease: The quality improvement design of this patient registry will generate large datasets that can provide insights into treatment patterns and related outcomes for DBS. Analysis of registry data will allow investigators to fill knowledge gaps in the current evidence base about DBS in PD, provide information that is applicable within a spectrum of clinical care environments, and yield recommendations for practice improvement that will enhance therapy outcomes for patients with Parkinson’s disease.

Back to Top

Click for a printer friendly version

Back